Pluristem Therapeutics Inc (PSTI)

[Scott999]

Jan 2017 presentation milestones. Take note of the “business development” section at the bottom. Here we are 2 years later. Not a single one complete. Along with many others. Should have just put DILUTE under that section. Absolute joke of leadership and a stock price to match. Absolute fools they are.

U.S /Europe phase III study initiation- Q1/2017

Japan pivotal study initiation – H2 2017

Closing on JV deal with Sosei- Q1/2017

Data from IC phase multinational phase II study, N=172 - early 2018

Interim result from Europe phase III (via adaptive pathway)- H2 2018/H1 2019


Data readout dose selection studies ARS- H1/2017

Contract with U.S. government for ARS – H2/2017

Initiation of pivotal study ARS NHP- H2/2017

Data readout phase I open label HCT- H2/2017

Preclinical data Fukushima- H1/2017

Preclinical data NYBC- H1/2017

Upcoming Milestones – 12 Months

Initiate advanced pivotal (pre-marketing) clinical trials:
• Critical Limb Ischemia (CLI) – U.S., EU, Japan
• Hip fracture – U.S., EU
• ARS
Clinical data readout
• Intermittent Claudication (IC)
• ARS- U.S. NIH dose selection trial
• Incomplete engraftment of hematopoietic cell transplantation – open label


Business development
• Japan- close the Sosei deal and form a JV
• U.S. – negotiating contract with government for ARS
• China- licensing/JV with Chinese partner